FDA Accepts Axsome Filing for Narcolepsy Drug AXS-12

The agency indicated it does not currently intend to convene an advisory committee to review the application, streamlining the path toward a potential market entry. AXS-12, which already holds orphan drug designation, is designed to manage cataplexy—a sudden, involuntary loss of muscle tone often triggered by intense emotions like laughter or stress. This symptom affects roughly 70% of those living with narcolepsy, a disorder characterized by a fundamental inability to regulate sleep-wake cycles. While the FDA's acceptance marks a significant procedural step, the medication remains unapproved as the review process moves toward its 2027 deadline.